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BACKGROUND/PURPOSE: Enterobacter cloacae is an important nosocomial pathogen responsible for 
various infections. Little is known about the synergistic effects of imipenem and colistin against multidrug-
resistant E. cloacae. Therefore, we investigated the in vitro effects of imipenem and colistin against a clinical 
isolate of multidrug-resistant E. cloacae.
METHODS: A strain of E. cloacae, designed Ent 831, was isolated from the sputum of a woman who de-
veloped severe pneumonia in a medical intensive care unit. Minimal inhibitory concentrations (MICs) of 
imipenem and colistin were determined by the agar dilution method. The synergistic effects were investi-
gated using the time-kill method.
RESULTS: MICs of imipenem and colistin for E. cloacae strain Ent 831 were 0.5 μg/mL and 1.0 μg/mL, re-
spectively. Using a standard ino culum (5 × 105 CFU/mL), synergism was shown with a concentration of two 
times the MICs of imipenem and colistin. Furthermore, four times the MIC of imipenem completely in-
hibited bacterial growth for more than 48 hours, but four times the MICs of colistin resulted in regrowth 
after 4 hours. There was no synergism between imipenem and colistin at two times the MICs against
a high concentration inoculum (6.24 × 106 CFU/mL). Nevertheless, imipenem, with or without colistin, at 
a concentration of four times MICs could inhibit the growth of bacteria for more than 48 hours.
CONCLUSION: High-dose imipenem, alone or in combination with colistin, is effective against multidrug-
resistant E. cloacae. Colistin alone, even at a high dose, is not effective. However, in vitro susceptibility to 
antimicrobial compounds does not always correlate with clinical success. Thus further testing of these 
antibiotic combinations in animal models is needed in order to predict their suitability for clinical use.
KEYWORDS: colistin, Enterobacter cloacae, imipenem, minimal inhibitory concentrations, time-kill study
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Introduction
Case Presentation
A 48-year-old woman with underlying acute promyelo-
cytic leukemia was admitted to a medical intensive care 
unit (ICU) with acute upper gastrointestinal tract bleed-
ing accompanied by acute respiratory failure. Suspected 
aspiration pneumonia developed over the left lung field 
after 48 hours of hospitalization. Initial sputum culture 
did not yield any pathogens. Empirical antimicrobial 
therapy with intravenous cefpirome (2 mg every 12 hours) 
was administered. On Day 13 of hospitalization, a new-
onset ventilator-associated pneumonia occurred over the 
right lung field (Figure 1A). Antimicrobial therapy was 
changed to intravenous imipenem 500 mg every 6 hours. 
A sputum culture yielded Enterobacter cloacae, which was 
only susceptible to amikacin, cefpirome and imipenem, 
but resistant to ampicillin, cefazolin, cefuroxime, ceftazi-
dime, ciprofloxacin, ertapenem, flomoxef, gentamicin, 
lomefloxacin, piperacillin and piperacillin/tazobactam, 
as assessed by a standard disc diffusion test.1 The patient 
passed away on Day 20 of hospitalization due to worsen-
ing pneumonia (Figure 1B), even after appropriate imi-
penem therapy for 7 days. The sputum culture obtained 
on the last day of hospitalization yielded a multidrug-
resistant E. cloacae strain with the same antibiogram as the 
previous isolate. The causative organism, designated strain 
Ent 831, was used in this study with the aim of finding 
potentially effective therapeutic options other than therapy 
with imipenem alone.
Enterobacter species are present in both adult and neo-
natal ICUs.2–6 Indeed, E. cloacae rarely cause diseases in 
healthy individuals. However, it is an important nosocomial 
pathogen responsible for various infections, e.g. bactere-
mia, lower respiratory tract infections, skin and soft-tissue 
infections, urinary tract infections, intra-abdominal in-
fections, septic arthritis, and osteomyelitis.7 The resistance 
rate of Enterobacter to extended-spectrum cephalosporins 
was 41.2% in German hospitals.3 Specific risk factors 
for infection with nosocomial multidrug-resistant strains 
of Enterobacter species include the recent use of broad-
spectrum cephalosporins, or aminoglycosides, and ad-
mission to the ICU.3,8–12 Enterobacter spp. that appears 
susceptible to cephalosporins at diagnosis may quickly 
develop into a resistant strain during therapy. Generally, 
the β-lactam rings of carbapenems and cefepime are more 
stable than those of third-generation cephalosporins 
against the AmpC β-lactamases produced by resistant 
strains of Enterobacter spp.7
Imipenem, a subgroup of carbapenems, has an ex-
tremely broad spectrum of activity against both Gram-
positive and Gram-negative bacteria, including E. cloacae.13 
As a fermentation product of the bacteria Bacillus colistinus, 
colistin was first discovered in 1949.14 The use of colistin 
was temporarily abandoned in the 1970s and early 1980s 
due to reports of a high incidence of nephrotoxicity.15,16 
However interest in colistin was rekindled following a rise 
in the prevalence of multidrug-resistant Gram-negative 
strains and it is now widely used for the treatment and 
eradication of Pseudomonas infections in patients with 
cystic fibrosis.17 Colistin is bactericidal and is active 
in vitro against a broad range of Gram-negative bacteria, 
e.g. Escherichia coli, Klebsiella species, Acinetobacter species, 
Enterobacter species, and it is highly active against Pseu-
domonas aeruginosa, with reported resistance rates of less 
than 5%.18–20 Based on the treatment of pneumonia 
Figure 1. (A) Day 13 of hospitalization. 
Chest X-ray shows new patches over 
the right lung field in addition to residual 
infiltration of the left lung. The con-
current sputum culture yielded a strain 
of multi-drug resistant Enterobacter cloacae. 
(B) Day 20 of hospitalization. Chest X-ray 
shows a worsening alveolar pattern of 
infiltration over the right lung field. The 
concurrent sputum culture yielded a 
strain of multi-drug resistant Enterobacter 
cloacae.
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caused by multidrug-resistant E. cloacae, both imipenem 
and colistin were selected to test the in vitro synergistic 
antimicrobial effects against the resistant isolate that 
resulted in the failure of imipenem therapy and an ulti-
mately fatal outcome for this patient.
Methods
Bacterial isolates
E. cloacae strain Ent 831 was isolated from the sputum of a 
woman with acute promyelocytic leukemia in the Chi-Mei 
Medical Center, Tainan on June 21, 2008.
Antimicrobial susceptibility testing
The minimal inhibitory concentrations (MICs) of cefepime 
(Bristol Myers Squibb Laboratories, Princeton, NJ, USA), 
imipenem (Merck Sharp & Dohme, West Point, PA, USA) 
and colistin sulfate (Sigma, St. Louis, MO, USA) were 
determined using agar dilution methods with Mueller-
Hinton agar according to the Clinical Laboratory Stan-
dards Institute.21 MIC is the lowest concentration of an 
antibiotic resulting in the complete inhibition of visible 
growth of an organism. The MIC for tigecycline was per-
formed using E-test strips (AB BIODISK, Solna, Sweden). 
Quality control was performed by testing E. coli ATCC 
25922 and P. aeruginosa ATCC 27853.
Determination of synergistic effects
Time-kill methods
E. cloacae Ent 831 was diluted to approximately 5 × 105 
CFU/mL and 6.24 × 106 CFU/mL for standard inoculum 
and high inoculum experiments, respectively.22 A 100-μL 
aliquot from each 10-fold serial dilution was plated on 
nutrient agar and bacterial colonies were counted after 0, 
2, 4, 6, 8, 12, 24, 30, 36 and 48 hours. The lower limit of 
detection was set at 10 colonies. All experiments were per-
formed at least twice. The inhibitory effects of imipenem 
and colistin, alone and in combination, against E. cloacae 
strain Ent 831 were evaluated. A bactericidal effect was de-
fined as a ≥ 3 log10 decrease from the starting inoculum 
with the effect sustained for at least 24 hours. Bacterio-
static activity was concluded if the inoculum size was main-
tained, or reduced by < 3 log10 CFU/mL, over 24 hours.
Synergism was defined as a ≥ 2 log10 CFU/mL reduction 
of bacterial colonies caused by combining two compounds 
when compared with the reduction numbers caused by the 
active single constituent after 24 hours. There was no sus-
tained inhibitory activity against E. cloacae strain Ent 831 
using a standard inoculum for at least 24 hours at ≤ the MIC 
for imipenem, colistin alone, or in combination. Therefore, 
the drug concentrations used in the time-kill studies started 
at double the MIC of each antimicrobial agent. To compare 
the dose-dependent effect, two concentrations (2 times and 
4 times) the MIC of imipenem (1.0 μg/mL and 2.0 μg/mL) 
and colistin (2.0 μg/mL and 4.0 μg/mL) were prepared.
Mechanism of antimicrobial resistance
Detection of the blaSHV, blaTEM, and blaCTX-M genes
Polymerase chain reaction was used (with plasmid DNA 
as the template) to amplify the entire sequences of the 
blaSHV-12 (forward primer: 5-ATG CGT TAT ATT CGC 
CTG TG-3 and reverse primer: 5-TTA GCG TTG CCA 
GTG CTC G-3) and those of other β-lactamase genes in-
cluding blaCTX-M-3, blaCTX-M-14 and blaTEM using specific 
primers as previously described.23–25 The purified ampli-
cons were sequenced and analyzed online at the National 
Center for Biotechnology Information website.
Results
The MIC of tigecycline, cefepime, imipenem and colistin 
against E. cloacae strain Ent 831 were 4.0 μg/mL, 2.0 μg/mL, 
0.5 μg/mL and 1.0 μg/mL, respectively. Polymerase chain 
reaction and subsequent sequence analysis confirmed the 
presence of blaSHV-12.
Standard inoculum experiments
Colistin at two times the MIC completely inhibited the 
growth of bacteria after 4 hours of incubation. However, 
the bacteria regrew to the same level as the control after 
24 hours (Figure 2A). Colistin at four times the MIC 
completely inhibited the growth of bacteria after 4 hours, 
but bacteria re-grew to the original inoculum size after 
12 hours and reached the level of the control after 
32 hours (Figure 2B).
Imipenem at two times the MIC reduced the growth of 
bacteria to approximately 5 × 102 CFU/mL after 8 hours 
of incubation. The bacteria then re-grew to reach the level 
of the control after 24–28 hours (Figure 2A). Imipenem at 
four times the MIC completely inhibited the growth of 
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bacteria after 2 hours, and this inhibitory effect persisted 
for more than 48 hours (Figure 2B).
A combination of imipenem and colistin at two times 
and four times MIC, completely inhibited bacterial growth 
after 4 and 2 hours, respectively. This inhibitory effect 
persisted for more than 48 hours.
High inoculum experiments
Colistin at two times the MIC reduced the growth of 
bacteria to approximately 5 × 102 CFU/mL after 2 hours. 
The bacteria then regrew to reach the level of the control 
after 24 hours (Figure 3A). Colistin at four times the MIC 
completely inhibited the growth of bacteria after 2 hours. 
The bacteria regrew to the original inoculum size after 
10 hours and reached control levels after 24 hours 
(Figure 3B).
Imipenem at two times the MIC reduced the growth of 
bacteria to approximately 5 × 103 CFU/mL after 8 hours. 
The bacteria regrew to reach the level of the control after 
24–28 hours (Figure 3A). Imipenem at four times the MIC 
completely inhibited the bacterial growth after 4 hours of 
incubation and this inhibitory effect persisted for more 
than 48 hours (Figure 3B).
A combination of colistin and imipenem at two times 
the MIC inhibited the growth of bacteria to < 50 CFU/mL 
after 6 hours, followed by regrowth to reach the inoculum 
size after 24 hours (Figure 3A). The combination of colistin 
and imipenem at four times the MIC completely inhibited 
growth after 4 hours and this inhibitory effect persisted 
for more than 48 hours (Figure 3B).
In summary, the use of imipenem, either with or without 
colistin, at four times the MIC was bactericidal against 
both standard and high inoculums of E. cloacae strain Ent 
831. Colistin alone at four times the MIC was only bacte-
riostatic for E. cloacae strain Ent 831, regardless of inocu-
lum concentration. A combination of imipenem and 
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Figure 2. Time-kill study for imipenem and colistin at (A) two times and (B) four times the minimal inhibitory concentration against 
Enterobacter cloacae strain Ent 831 with a standard inoculum.
Figure 3. Time-kill study for imipenem and colistin at (A) two times and (B) four times the minimal inhibitory concentration against 
Enterobacter cloacae strain Ent 831 with a high inoculum.
10
8
6
4
2
0
0 4 8 12 16 20 24 28 32 36 40 44 48 52 56
Time (hr)
lo
g 
C
FU
/m
L
Control
Combined
Imipenem
Colistin
10
8
6
4
2
0
0 4 8 12 16 20 24 28 32 36 40 44 48
Time (hr)
lo
g 
C
FU
/m
L
Control
Combined
Imipenem
Colistin
A B
 321
Synergism of imipenem and colistin against E. cloacae
colistin at two times the MIC was bactericidal for the 
standard E. cloacae strain Ent 831 inoculum. Either imi-
penem or colistin alone at two times the MIC were bacte-
riostatic for the E. cloacae strain Ent 831, regardless of 
inoculum concentration.
Discussion
Imipenem has excellent broad-spectrum activities against 
aerobic and anaerobic Gram-positive and Gram-negative 
bacteria. Colistin is regarded as being bactericidal and 
is active in vitro against a broad range of Gram-negative 
bacteria, e.g. Acinetobacter species, Citrobater spp., E. coli, 
Enterobacter spp., Haemophilus influenzae, Klebsiella spp., 
Salmonella and Shigella species.19 E. cloacae are resistant to 
cephalosporins due to the mechanism of derepressive 
production of the ampC enzyme and/or production of ex-
tended spectrum beta-lactamase (ESBL).10,26–28 Resistance 
to carbapenems is unusual and may be due to the produc-
tion of metallo-β-lactamases (MBL).29 The synergistic 
activity of combinations of colistin and rifampin or imi-
penem against an MBL-producing E. cloacae strain has 
been demonstrated and this combination of three drugs 
successfully treated a severe E. cloacae infection.30
The antimicrobial resistance mechanism of E. cloacae 
strain Ent 831 includes an ESBL (SHV-12) and, probably, 
an intrinsic AmpC β-lactamase, similar to that in previous 
reports.12,24,25 Therefore, it would be reasonable to expand 
these studies to cover multidrug-resistant E. cloacae in 
Taiwan. Antimicrobial susceptibility testing revealed that 
E. cloacae strain Ent 831 was susceptible to amikacin, cef-
pirome or cefepime, imipenem and colistin. Owing to the 
production of SHV-12 by E. cloacae strain Ent 831, the 
possibility of the therapeutic failure of cefpirome or 
cefepime against this isolate is real.12,24,25,31 Although 
tigecycline was highly active against ESBL-producing 
E. cloacae in our previous report,32 E. cloacae strain Ent 831 
was not susceptible to tigecycline (MIC > 2 μg/mL) in the 
current study, highlighting the need to continue moni-
toring the activity of this new compound against ESBL-
producing isolates.
In this study, we used the time-kill method to evaluate 
the synergism antimicrobials against a multidrug-resistant 
strain of E. cloacae. The synergistic effect of imipenem 
and colistin was shown when both drugs were combined 
at two times the MIC in standard inoculum experiments. 
However, a combination of both drugs at two times the 
MIC was only bacteriostatic in the high inoculum experi-
ments. Regardless inoculum concentration, a high dose 
of imipenem (4 times MIC), either alone or in combi-
nation with colistin (4 times MIC) showed bactericidal 
activity. Surprisingly, colistin at both two times MIC 
and four times MIC was only bacteriostatic in both the 
standard and high inoculum experiments. Accordingly, 
despite its apparent susceptibility to colistin, multidrug-
resistant E. cloacae should not be treated with colistin 
monotherapy.
The limited usage of colistin in the 1980s was due to 
reports of a high incidence of nephrotoxicity.15,16 Early clin-
ical reports of severe toxicity are likely to have occurred as 
a result of inappropriate patient selection, higher than 
recommended doses and inappropriate monitoring.18 The 
time-kill study demonstrated the synergistic effects of an-
tibiotics against E. cloacae in vitro. However, one limitation 
in this study is that we did not include an isolate that was 
not susceptible to imipenem or colistin. Furthermore, 
in vitro susceptibility to antimicrobial compounds does 
not always correlate with in vivo activity. In addition, the 
nephrotoxicity of colistin may still be a concern in clinical 
practice. Further testing of these antibiotic combinations 
in animal models is needed in order to predict their suita-
bility for clinical use in humans.
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